RPHM RENEO PHARMACEUTICALS INC

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the following conferences in September, as detailed below:

Baird Global Healthcare Conference (September 13-14, 2022)

Location: InterContinental New York Barclay, Morgan Suite, Mezzanine Level

Presentation: Tuesday, September 13, 2022, 10:50AM ET (Session IV)

11th Annual SVB Securities Healthcare Summit (September 21-23, 2022)

Location: Rosewood Miramar Beach, Montecito, California

Ladenburg Thalmann Annual Healthcare Conference (September 29, 2022)

Location: Sofitel Hotel, New York, NY, Track 3 – Montmarte

Fireside Chat: Thursday, September 29, 2022, 11:00 AM ET

Links to the presentations will be posted on the section of the Reneo Pharmaceuticals corporate website, under Events and Presentations.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Joyce Allaire

Managing Director

LifeSci Advisors, LLC

Danielle Spangler

Investor Relations

Reneo Pharmaceuticals, Inc.



EN
06/09/2022

Underlying

RPHMRENEO PHARMACEUTICALS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RENEO PHARMACEUTICALS INC

 PRESS RELEASE
Free
RPHM RENEO PHARMACEU...

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Conc...

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 -- Shares to trade on Nasdaq under the new ticker ...

October 4, 2024 1 EN
 PRESS RELEASE
Free
RPHM RENEO PHARMACEU...

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with On...

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure – Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) today announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo’s stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. (“OnKure”). The closing of the ...

October 3, 2024 1 EN
 PRESS RELEASE
Free
RPHM RENEO PHARMACEU...

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights On May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the “Merger”).The...

August 13, 2024 1 EN
 PRESS RELEASE
Free
RPHM RENEO PHARMACEU...

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

Reneo Pharmaceuticals and OnKure Announce Proposed Merger Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmac...

May 13, 2024 1 EN
 PRESS RELEASE
Free
RPHM RENEO PHARMACEU...

Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results

Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or sec...

May 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch